Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526419 · ClinicalTrials.gov registry record
Exparel PK and Breast Milk Excretion
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 30
- Enrollment target
NCT03526419: Completed study, sponsored by University of Minnesota.
NCT03526419 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03526419 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Investigate the pharmacokinetics of Liposomal Bupivacaine and its excretion in breast milk in patients undergoing TAP block after their scheduled C -section delivery
Primary Outcome
AUC for the milk/plasma drug ratio
Interventions
- DRUG Bupivacaine liposome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2019-09-01 |
What the finished NCT03526419 record still lists
NCT03526419 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Bupivacaine liposome is the first listed.
NCT03526419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03526419 about?
NCT03526419 is a clinical study titled "Exparel PK and Breast Milk Excretion". Investigate the pharmacokinetics of Liposomal Bupivacaine and its excretion in breast milk in patients undergoing TAP block after their scheduled C -section delivery
What is the current status of trial NCT03526419?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2019-02-01. Estimated completion is 2019-09-01.
What interventions are being tested in trial NCT03526419?
The interventions under investigation include: Bupivacaine liposome (DRUG).
Who is sponsoring clinical trial NCT03526419?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI